Versant Capital Management’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15.3K Sell
261
-33
-11% -$1.38K ﹤0.01% 2063
2026
Q1
$9.47K Buy
294
+192
+188% +$7.11K ﹤0.01% 2163
2025
Q4
$4.29K Hold
102
﹤0.01% 2303
2025
Q3
$3.5K Sell
102
-12
-11% -$344 ﹤0.01% 2317
2025
Q2
$3.08K Sell
114
-816
-88% -$23.6K ﹤0.01% 2296
2025
Q1
$27.6K Buy
930
+862
+1,268% +$32.9K ﹤0.01% 1156
2024
Q4
$2.69K Hold
68
﹤0.01% 1986
2024
Q3
$2.31K Hold
68
﹤0.01% 1527
2024
Q2
$1.47K Buy
+68
New +$1.43K ﹤0.01% 1590
2023
Q4
Sell
-54
Closed -$1.21K 2020
2023
Q3
$1.21K Sell
54
-21
-28% -$540 ﹤0.01% 1477
2023
Q2
$1.91K Buy
+75
New +$1.82K ﹤0.01% 1387

Other funds holding VCYT

Versant Capital Management's VCYT Position: Q2 2026 in Review

Versant Capital Management reduced its Veracyte (VCYT) stake by 11% in Q2 2026, selling an estimated $1.38K and leaving 261 shares worth $15.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2063.

Versant Capital Management first reported a position in VCYT in Q2 2023 and has held it in 11 quarters since. The position peaked at $27.6K in Q1 2025. 32 funds tracked by Wall St. Rank hold VCYT as of Q2 2026.

  • Versant Capital Management held 261 shares of Veracyte worth $15.3K as of Q2 2026.
  • Versant Capital Management sold 33 Veracyte shares in Q2 2026, an estimated $1.38K.
  • Veracyte made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2063 holding.
  • Versant Capital Management first reported a position in Veracyte in Q2 2023 and has held it in 11 quarters since.
  • Versant Capital Management's Veracyte position peaked at $27.6K in Q1 2025.
  • 32 funds tracked by Wall St. Rank held Veracyte as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.